August 14th 2024
In part 2 of this interview with Deborah Birx, MD, she highlights that ActivePure Technology provides a continuous decontamination solution that operates independently of manual intervention to reduce HAIs.
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Containing an Outbreak of Carbapenem-Resistant Acinetobacter baumannii in a COVID-19 Isolation Unit
October 20th 2022COVID-19 isolation wards should employ additional contact precautions and environmental cleaning alongside regular COVID-19 precautions, such as personal protective equipment, in order to prevent multidrug-resistant infections.
Read More
Novel Antibiotics for Resistant Pathogens: Results of ATTACK Trial for Sulbactam-Durlobactam
April 26th 2022Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.
Read More
Identifying High-Risk Recurrent Clostridioides Difficile Patients for Bezlotoxumab
April 18th 2022The greatest risk factors for recurrent Clostridioides difficile infection (CDI) were age of at least 65 years, severe primary CDI, and use of non-CDI antibiotics. Patients with these risk factors should be prioritized for bezlotoxumab therapy.
Read More